Selective inhibition of hepatic stellate cell and fibroblast-derived LOXL1 attenuates BDL- and Mdr2 −/− -induced cholestatic liver fibrosis
American Journal of Physiology-Gastrointestinal and Liver Physiology · 01.12.2023 · 325 (6) · G608-G621
DOI: 10.1152/ajpgi.00004.2023 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Physiology-Gastrointestinal and Liver Physiology, erschienen am 01.12.2023. Verfasst von Xuzhen Yan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Experimental and Translational Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Amino Acid Oxidoreductases, Hepatic Stellate Cells, ATP-Binding Cassette Sub-Family B Member 4, Fibroblasts. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: MOST | National Natural Science Foundation of China (NSFC).
Abstract (Originalsprache)
Selectively, inhibition of HSC/fibroblasts-derived LOXL1 by AAV2/6-shLoxl1 could reduce collagen deposition, HSC/fibroblasts proliferation, and cholestatic liver fibrosis progression. In addition, overexpression of LOXL1 significantly promoted HSC/fibroblast proliferation by activating the PDGFRß/PI3K and ERK signaling pathways in vitro.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental and Translational Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China.
- Beijing Clinical Medicine Institute, Beijing, People's Republic of China.
- National Clinical Research Center of Digestive Diseases, Beijing, People's Republic of China.
- Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China.
- Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, Beijing, People's Republic of China.
- Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China.
ORCID-Profile: Hong You
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
Zitieren
APA
Yan, X., Zhang, N., Wei, L., Zhang, W., Huang, T., Li, W., Chen, W., Yang, A., & You, H. (2023). Selective inhibition of hepatic stellate cell and fibroblast-derived LOXL1 attenuates BDL- and Mdr2 −/− -induced cholestatic liver fibrosis. American Journal of Physiology-Gastrointestinal and Liver Physiology, 325(6), G608-G621. https://doi.org/10.1152/ajpgi.00004.2023
Vancouver
Yan X, Zhang N, Wei L, Zhang W, Huang T, Li W, et al. Selective inhibition of hepatic stellate cell and fibroblast-derived LOXL1 attenuates BDL- and Mdr2 −/− -induced cholestatic liver fibrosis. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2023;325(6):G608-G621. doi:10.1152/ajpgi.00004.2023
BibTeX
@article{Yan2023,
author = {Yan, Xuzhen and Zhang, Ning and Wei, Luyang and Zhang, Wen and Huang, Tao and Li, Weiyu and Chen, Wei and Yang, Aiting and You, Hong},
title = {Selective inhibition of hepatic stellate cell and fibroblast-derived LOXL1 attenuates BDL- and Mdr2 −/− -induced cholestatic liver fibrosis},
journal = {American Journal of Physiology-Gastrointestinal and Liver Physiology},
year = {2023},
volume = {325},
number = {6},
pages = {G608--G621},
doi = {10.1152/ajpgi.00004.2023}
}
EUVIMED